Dr. Reddy's Laboratories
Search results
5 days ago · Driven by our collective vision of transforming healthcare and transforming patients’ lives, Biocon Biologics is making healthcare affordable and importantly accessible to millions of patients and their families across the world.
Biocon Biologics is today one of the frontrunners in the global biosimilars industry, working to provide patients access to affordable biologics and enable health equity worldwide. Driven by a Purpose to Address Unmet Needs for Affordable Biologics.
5 days ago · Biocon is an innovation led fully integrated biopharmaceutical company that develop affordable biosimilars, generic formulations & complex APIs.
5 days ago · Biocon Biologics Ltd (BBL), a global, fully integrated biosimilars company and a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), has received approval from the European Medicines Agency (EMA) to manufacture biosimilar Bevacizumab at its new, world-class, multi-product monoclonal antibodies (mAbs) drug substance facility at Bengaluru. This approval will provide significant additional capacity to address patients’ needs across markets in Europe.
Biocon Biologics Limited (BBL) is a fully integrated, innovation-led company committed to transforming patients’ lives by enabling affordable access to high-quality biosimilars for patients and healthcare systems, either directly or through a network of partners and distributors, in over 100+ countries.
5 days ago · Biocon Biologics received approval from the European Medicines Agency to manufacture biosimilar Bevacizumab at its new, multi-product monoclonal antibodies drug substance facility in Bengaluru, the drugmaker says in a press statement released today. Biocon Biologics is an international fully integrated biosimilar subsidiary of listed Biocon Limited. Biocon Biologics offers a portfolio of eight commercialised biosimilars across the globe which include Insulin Glargine, Insulin Aspart ...
Biocon Biologics offers one of the industry’s widest and deepest biosimilars portfolios, including monoclonal antibodies, insulin and insulin analogs and conjugated recombinant proteins.
Biocon Biologics is a global leader in the development and commercialization of biosimilars. Our cutting-edge science, extensive portfolio of biosimilars, and commitment to quality and compliance make us a trusted choice for healthcare providers and patients worldwide.
4 days ago · Biocon Biologics received EMA approval to manufacture biosimilar Bevacizumab in Bengaluru, providing additional capacity to address patients' needs in Europe for treating cancer. The Bengaluru facility was also approved for biosimilar Trastuzumab manufacturing. EMA renewed GMP certificates for Biocon's facilities in Bengaluru and Malaysia. USFDA issued four observations after inspecting Biocon's Andhra Pradesh plant, concluding inspections on June 21, 2024.
5 days ago · New Delhi: Biocon on Monday said its unit Biocon Biologics has received approval from the European Medicines Agency (EMA) to manufacture biosimilar Bevacizumab at its new facility at Bengaluru.
